Geiger Susi (142 results)

Condition: Very Good. Former library copy. Pages intact with possible writing/highlighting. Binding strong with minor wear. Dust jackets/supplements may not be included. Includes library markings. Stock photo provided. Product includes identifying sticker. Better World Books: Buy Books. Do Good.

paperback. Condition: Very Good.

paperback. Condition: Fine.

Condition: Very Good. 2005. Paperback. Very good copy with minor shelf wear. Light wear to corners, remains very good. . . . . Books ship from the US and Ireland.

Condition: Very Good. 2005. Paperback. Very good copy with minor shelf wear. Light wear to corners, remains very good. . . . .

Softcover. Condition: Très bon. Ancien livre de bibliothèque avec équipements. Edition 2011. Ammareal reverse jusqu'à 15% du prix net de cet article à des organisations caritatives. ENGLISH DESCRIPTION Book Condition: Used, Very good. Former library book. Edition 2011. Ammareal gives back up to 15% of this item's net price to charity organizations. …

Condition: New.

Paperback or Softback. Condition: New. Market Studies. Book.

Condition: New.

PAP. Condition: New. New Book. Shipped from UK. Established seller since 2000.

Condition: As New. Unread book in perfect condition.

Paperback. Condition: Very Good. The book has been read, but is in excellent condition. Pages are intact and not marred by notes or highlighting. The spine remains undamaged.

PAP. Condition: New. New Book. Shipped from UK. Established seller since 2000.

Condition: As New. Unread book in perfect condition.

Condition: New.

Paperback or Softback. Condition: New. Peak Pharma: Toward a New Political Economy of Health. Book.

Condition: good. May show signs of wear, highlighting, writing, and previous use. This item may be a former library book with typical markings. No guarantee on products that contain supplements Your satisfaction is 100% guaranteed. Twenty-five year bookseller with shipments to over fifty million happy customers.…

Condition: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Paperback. Condition: New. This book argues that we have reached the 'peak' of a particular model for pharmaceutical production - the neoliberal value model that has been in place since the early 1980s. 'Peak' designates a state where a value model's contradictions become exacerbated to a point where the system cannot but change: it is a point where an industry's products become too expensive and its resources exhausted, and where the coalitions that have held up that particular value model disintegrate. In other words, it is the point where an industry collapses under its own greed, of having captured too much value for itself, leaving too little to the other actors in the system.Peak Pharma argues that the neoliberal pharmaceutical system is reaching its 'peak' in several vital respects - peak pricing, peak concentration, peak financialization, and peak expansion. It uses the term to signal the crisis and possible end of an era-defining business model in the pharmaceutical sector. The book presents a synthesis of the authors' decade-long empirical investigations into social movements contesting the pharmaceutical market. It brings together a large body of knowledge that is currently spread across political economy, sociology, STS, organization studies, and the history of medicine, to follow the neoliberal dynamics that have engendered an acceleration toward 'peak' over the span of the last 40 years. It traces the emergence of different voices and groups that have contested this evolution, particularly around specific crisis points and revelatory moments, including the fight for access to HIV/AIDS medicines, the global health era, pharmaceutical corporate social responsibility, the advent of personalized medicine and digital health, Covid-19, and others. The authors trace the shifting coalitions between the pharmaceutical industry, patient organisations, and governments that kept propping up the neoliberal value system throughout this evolution. They show that the recent acceleration toward peak has led many centrist voices from patient organizations, academia and politics to start changing course from market repair to imagining alternative pharmaceutical economies, prominently including imaginaries around the pharmaceutical commons. The book closes with a set of recommendations for policy makers and civil society actors interested in fostering an alternative political economy of health.This is an open access title available under the terms of a [CC BY-NC-ND 4.0 International] licence. It is free to read at Oxford Scholarship Online and offered as a free PDF download from OUP and selected open access locations.…

Paperback. Condition: Very Good.

Condition: Used. pp. 288.

Paperback. Condition: New. Market studies is a newly emerging field dedicated to understanding the origins, core concepts, theories and methods currently being used and developed to examine markets in the making. Providing a unique overview that introduces, positions and develops this highly fertile area of research, Market Studies is the first book to consolidate its themes, tools and methods in a single, comprehensive volume. Topics covered include: market organization and design; performativity in and around markets; valuation; market places and spaces; methods that may be utilized in studying markets; the field's relation to adjacent disciplines; the future of markets. Deploying a sensitivity for the socio-material constitution of markets, the authors put market practices at the centre of inquiry and offer insights into the future and potential impact of market studies research. The contemporary, practical and interdisciplinary approach is strengthened by multiple examples of original empirical research into markets.…

Condition: Used. pp. 288.

Paperback. Condition: New. This book argues that we have reached the 'peak' of a particular model for pharmaceutical production - the neoliberal value model that has been in place since the early 1980s. 'Peak' designates a state where a value model's contradictions become exacerbated to a point where the system cannot but change: it is a point where an industry's products become too expensive and its resources exhausted, and where the coalitions that have held up that particular value model disintegrate. In other words, it is the point where an industry collapses under its own greed, of having captured too much value for itself, leaving too little to the other actors in the system.Peak Pharma argues that the neoliberal pharmaceutical system is reaching its 'peak' in several vital respects - peak pricing, peak concentration, peak financialization, and peak expansion. It uses the term to signal the crisis and possible end of an era-defining business model in the pharmaceutical sector. The book presents a synthesis of the authors' decade-long empirical investigations into social movements contesting the pharmaceutical market. It brings together a large body of knowledge that is currently spread across political economy, sociology, STS, organization studies, and the history of medicine, to follow the neoliberal dynamics that have engendered an acceleration toward 'peak' over the span of the last 40 years. It traces the emergence of different voices and groups that have contested this evolution, particularly around specific crisis points and revelatory moments, including the fight for access to HIV/AIDS medicines, the global health era, pharmaceutical corporate social responsibility, the advent of personalized medicine and digital health, Covid-19, and others. The authors trace the shifting coalitions between the pharmaceutical industry, patient organisations, and governments that kept propping up the neoliberal value system throughout this evolution. They show that the recent acceleration toward peak has led many centrist voices from patient organizations, academia and politics to start changing course from market repair to imagining alternative pharmaceutical economies, prominently including imaginaries around the pharmaceutical commons. The book closes with a set of recommendations for policy makers and civil society actors interested in fostering an alternative political economy of health.This is an open access title available under the terms of a [CC BY-NC-ND 4.0 International] licence. It is free to read at Oxford Scholarship Online and offered as a free PDF download from OUP and selected open access locations.…

Paperback. Condition: New. Concerned Markets tackles the intersection between markets and politics, investigating the very current issue of designing markets to include multiple values.When political, social, technological and economic interests, values, and perspectives interact, market order and performance become contentious issues of debate. Such 'hot' situations are becoming increasingly common and make for rich sites of research. With expert empirical contributions investigating the organization of such 'concerned' markets, this book is positioned at the centre of the rapidly growing area of interdisciplinary market studies. Markets investigated include those for palm oil, primary health care and functional foods. The authors also examine markets and environmental concerns as well as better market design for those at the bottom of the pyramid.Scholars, postgraduate and PhD level students in finance, economic sociology, marketing, organization theory and economics will find this book essential reading. Policymakers and practitioners will benefit from the fresh insight into the design and maintenance of market systems.Contributors include: L. Araujo, F. Azimont, R. Chakrabarti, F. Cochoy, S. D'Antone, G. Dix, S. Geiger, D. Harrison, J. Hauber, L. Johansson, H. Kjellberg, A. Mallard, K. Mason, W.I. Onyas, C. Ruppert-Winkel, A. Ryan, R. Spencer, I. Stigzelius.…

PAP. Condition: New. New Book. Shipped from UK. Established seller since 2000.

Paperback. Condition: Brand New. In Stock.

Condition: New.

Condition: new.